GLP1R and type 2 diabetes mellitus: Our results are consistent with the scientific literature on the benefits of GLP-1 receptor agonists, reinforcing the value of semaglutide in comprehensive diabetes care by demonstrating not only improvements in glycemic control and weight management but also reductions in CVD risk factors and overall mortality among patients with T2D [59,60].